TY - JOUR AB - Aim: To assess the impact of (68)Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/ Computed Tomography (PET/CT) on management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans were retrospectively reviewed before and after (68)Ga-PSMA PET/CT in 100 patients with BCR and change in plans recorded. Results: Management changed after (68)Ga-PSMA PET/CT in 39 patients (39%). These occurred in 23/68 (33.8%) of patients with radical prostatectomy (RP) and 16/32 (50%) of patients previously treated with radical radiotherapy. Positive scan (P < 0.001) and higher Prostate Specific Antigen (PSA) (P = 0.024) were associated with management changes. No significant association with management change was found with Gleason grade, stage, presence of metastatic disease, PSA velocity or doubling time. Conclusion:(68)Ga-PSMA PET/CT altered management in 39% of patients with BCR, and occurred more often in patients with radical radiotherapy treatment, a positive (68)Ga-PSMA scan and higher PSA level. AU - Afaq,A AU - Alahmed,S AU - Chen,S-H AU - Lengana,T AU - Haroon,A AU - Payne,H AU - Ahmed,H AU - Punwani,S AU - Sathekge,M AU - Bomanji,J DO - 10.2967/jnumed.117.192625 PY - 2017/// SN - 1535-5667 TI - (68)Ga-PSMA PET/CT impact on prostate cancer management. T2 - Journal of Nuclear Medicine UR - http://dx.doi.org/10.2967/jnumed.117.192625 ER -